Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Stimcell EnergeticsSTME 26 3-Year EBITDA Growth Rate is 44.70% as of Feb. 2026, which is 135% above its 10-year median of 19.00. GuruFocus rates STME with a GF Score™ of 26/100. The stock has 4 warning signs investors should review. Among 693 Medical Devices & Instruments companies, Stimcell Energetics ranks better than 86.15% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 44.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 45.90% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 31.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Stimcell Energetics was 64.20% per year. The lowest was -451.60% per year. And the median was 19.00% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Stimcell Energetics 3-Year EBITDA Growth Rate Related Terms
STME vs TRIB, AIDX, VVOS: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Stimcell Energetics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stimcell Energetics 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Stimcell Energetics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Stimcell Energetics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 44.70% mean?
Stimcell Energetics (STME) has a 3-Year EBITDA Growth Rate of 44.70% as of Feb. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Stimcell Energetics and its competitors. This is 135% above median its historical median of 19.00. According to the industry distribution chart, Stimcell Energetics ranks #96 out of 693 companies in the Medical Devices & Instruments industry, placing it in the top 13.9%.
Is Stimcell Energetics' 3-Year EBITDA Growth Rate too high?
Stimcell Energetics' current 3-Year EBITDA Growth Rate of 44.70% is 135% above median its 10-year median of 19.00. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.10. Stimcell Energetics' value of 44.70% is 451.9% above this industry median. Based on the distribution chart, Stimcell Energetics ranks #96 out of 693 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Stimcell Energetics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Stimcell Energetics' 3-Year EBITDA Growth Rate compare to TRIB and AIDX?
According to the Medical Devices & Instruments industry distribution chart, Stimcell Energetics ranks #96 out of 693 companies for 3-Year EBITDA Growth Rate. This places Stimcell Energetics in the top 14% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.10. Stimcell Energetics' value of 44.70% is 451.9% above this benchmark. While the company's 10-year median is 19.00 vs. the industry median of 8.10, Stimcell Energetics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.10, based on 693 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Stimcell Energetics's current 3-Year EBITDA Growth Rate of 44.70% is 451.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Stimcell Energetics and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stimcell Energetics's current 3-Year EBITDA Growth Rate is 44.70%, which is 135% above median its own 10-year median of 19.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stimcell Energetics stock overvalued right now?
Stimcell Energetics (STME) has a current 3-Year EBITDA Growth Rate of 44.70%. The current 3-Year EBITDA Growth Rate is 44.70%, which is 135% above median its 10-year median of 19.00 and 451.9% above the Medical Devices & Instruments industry median of 8.10. Stimcell Energetics' overall GF Score™ is 26/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Stimcell Energetics (STME), the current 3-Year EBITDA Growth Rate is 44.70% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Stimcell Energetics Inc is a biotech company focused on the discovery, development, and commercialization of therapeutic and non-therapeutic products that enhance cellular function, promote general wellness, and alleviate health complications, including, but not limited to: aging, diabetes, high blood pressure, neuropathy, and kidney function. The company's main focus is on continued research and development of its eBalance Technology and its eBalance Home System.
26GF Score
Get the complete analysis for STME
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STME has been successfully added to your 
